J Respir Med Lung Dis | Volume 2, Issue 1 | Case Report | Open Access

Malignant Pleural Mesothelioma with Tumor-Associated Blood/Tissue Eosinophilia and Increased Blood TARC/ CCL17 Level: A Case Report

Yorozu H, Ito Y^*, Honjo O and Koba H

Department of Pulmonary Medicine, Teine Keijinkai Hospital, Japan

^*Correspondance to: Ito Y 

Fulltext PDF

Abstract

Malignant pleural mesothelioma (MPM) is a cancer of the pleura. There is an established correlation between asbestos exposure and MPM. Despite the ban of asbestos, MPM incidence is still expected to rise because of the very long lag-times between exposure and diagnosis. However, MPM remains a universally fatal cancer with median survival from diagnosis being only 9-12 months. We described a 60-year-old male with MPM presenting with various clinical manifestations, including tumorassociated blood eosinophilia, tumor-associated tissue eosinophilia, increased platelet number, hypercoagulable state and increased blood thymus and activation-regulated chemokine (TARC)/ CCL17 level. TARC/CCL17 might be a biomarker and therapeutic target for a subpopulation of patients with MPM.

Citation:

Yorozu H, Ito Y, Honjo O, Koba H. Malignant Pleural Mesothelioma with Tumor-Associated Blood/Tissue Eosinophilia and Increased Blood TARC/CCL17 Level: A Case Report. J Respir Med Lung Dis. 2017; 2(1): 1012.